<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="2719,48432">Angiotensin II</z:chebi> type 1 (AT(1)) receptor signaling has been implicated in cerebral microvascular alterations associated with <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, <z:hpo ids='HP_0003124'>hypercholesterolemia</z:hpo>, and <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Platelets, which express AT(1) receptors, also appear to contribute to the thrombogenic and <z:mp ids='MP_0001845'>inflammatory responses</z:mp> that are elicited by these pathological conditions </plain></SENT>
<SENT sid="2" pm="."><plain>This study assesses the role of AT(1) receptor activation on platelet-leukocyte-endothelial cell interactions elicited in cerebral microvasculature by <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and reperfusion </plain></SENT>
<SENT sid="3" pm="."><plain>Intravital microscopy was used to monitor the <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> of platelets and leukocytes that were labeled with different <z:chebi fb="0" ids="51217">fluorochromes</z:chebi>, whereas dihydrorhodamine-123 was used to quantify oxygen radical production in cerebral surface of mice that were either treated with the AT(1) receptor <z:chebi fb="4" ids="48705">agonist</z:chebi> Val-<z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> (ANG II) or subjected to bilateral common carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> (BCCAO) followed by reperfusion </plain></SENT>
<SENT sid="4" pm="."><plain>ANG II elicited a dose- and time- dependent increase in platelet-leukocyte-endothelial cell interactions in cerebral venules that included rolling platelets, adherent platelets on the leukocytes and the endothelial cells, rolling leukocytes, and adherent leukocytes </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of these interactions were attenuated by treatment with either P-selectin or P-selectin <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> ligand 1 (PSGL-1) antibody </plain></SENT>
<SENT sid="6" pm="."><plain>The AT(1) receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> <z:chebi fb="0" ids="3347">candesartan</z:chebi> and <z:chebi fb="0" ids="6541">losartan</z:chebi> as well as diphenyleneiodonium, an inhibitor of <z:chebi fb="0" ids="5086">flavoproteins</z:chebi> including <z:chebi fb="0" ids="13392">NAD(P)H</z:chebi> oxidase, significantly reduced the platelet-leukocyte-endothelial cell interactions elicited by either ANG II administration or BCCAO/reperfusion </plain></SENT>
<SENT sid="7" pm="."><plain>The increased oxygen radical generation elicited by BCCAO/reperfusion was also attenuated by <z:chebi fb="0" ids="3347">candesartan</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>These findings are consistent with an AT(1) receptor signaling mechanism, which involves oxygen radical production and ultimately results in P-selectin- and PSGL-1-mediated platelet-leukocyte-endothelial cell interactions in the cerebral microcirculation </plain></SENT>
</text></document>